Market Trends of Global Autoimmune Treatment Industry
This section covers the major market trends shaping the Autoimmune Treatment Market according to our research experts:
Multiple Sclerosis segment is Expected to Hold Large Market Share
Multiple Sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body's immune system is directed against the central nervous system (CNS). According to the Atlas of Multiple Sclerosis 3rd Edition, 2020, by the Multiple Sclerosis (MS) International Federation, nearly 2.8 million people worldwide are estimated to be living with multiple sclerosis, which equates to 1 in 3,000 people in the world living with MS and in countries with the highest prevalence, as many as 1 in every 300 people have MS. Also, Multiple Sclerosis prevalence has increased in every world region, rising from 2.3 million people affected in 2013 to 2.8 million in 2020. The high prevalence of MS cases globally is expected to propel the market for the studied segment. Public Health England Report titled 'Multiple sclerosis: prevalence, incidence and smoking status - data briefing' published in February 2020 reported that the estimated prevalence of multiple sclerosis was 190 cases per 100,000 population which equates to 105,800 individuals in England. In September 2020, Genentech, a member of the Roche Group, initiated an innovative Phase III clinical trial program for its investigational medicine, fenebrutinib, in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial program for Ocrevus (ocrelizumab) and a distinct Ocrevus trial specifically to support African-American and Hispanic- and Latinx-American patients with Multiple sclerosis. In March 2021, experts in the United Kingdom have planned to test a range of drugs already approved for other illnesses for the treatment of multiple sclerosis (MS) in a world-first 'mega-trial', which is a multi-armed trial named Octopus. Similarly, in March 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson received the United States Food and Drug Administration (FDA) approval for its Ponvory(ponesimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting, and active secondary-progressive forms of MS. Thus, given the increasing pipeline of drugs and new product launches along with the high prevalence of MS, the studied segment is expected to witness significant growth over the forecast period.
North America Dominates the Market and Expected to do same in the Forecast Period
North America is expected to dominate the overall autoimmune treatment market, throughout the forecast period. This is due to factors such as the rising incidence and prevalence of autoimmune diseases in the region. The United States has the highest incidence of autoimmune disorders (AD), with 15 to 30 million patients affected, according to the Autoimmune Registry, 2020. The National Institutes of Health (NIH) launched two funding opportunities in March 2021 through the initiative Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases (AMP AIM) to support research into autoimmune diseases. Additionally, in November 2020, Myriad Genetics, Inc. and Integrated Prescription Management (IPM) agreed to create an innovative program for persons with rheumatoid arthritis (RA). The government is anticipated to spend more money in the future on autoimmune illness research and development due to the demand for greater funding. A considerable improvement in the diagnosis, treatment and management of autoimmune diseases can be achieved by increased NIH funding.
